Better Therapeutics, Inc. (Nasdaq: BTTX) is a prescription digital therapeutics company that completed its business combination with Mountain Crest Acquisition Corp. II, sponsored by Mountain Crest Capital, in October 2021. The company, focused on developing software-based treatments targeting cardiometabolic diseases including type 2 diabetes and hypertension, listed on the Nasdaq following the de-SPAC transaction in the healthcare sector. By early 2024, Better Therapeutics had suspended development activities for its lead product and was exploring strategic alternatives, reflecting broader headwinds in the digital therapeutics space. The March 2024 8-K filing captures a pivotal moment in the company's corporate lifecycle. For complete filing history, status updates, and sponsor data on BTTX and thousands of other SPAC transactions, sign up for full access at SpacDesk.